ValueAct’s Valeant Problem

Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?

July 21, 2016

Twitter
LinkedIn
Pinterest
Tumblr
Copy
Link copied
Print
Email

Michael Nagle

Photo credit: Bloomberg
By Michelle Celarier

ValueAct Capital Management’s Jeffrey Ubben has carefully cultivated a reputation as a good-guy activist who works with management to get results — a reputation that was built in part on his tremendous success with Canadian drugmaker Valeant Pharmaceuticals International.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.